<DOC>
	<DOCNO>NCT01134016</DOCNO>
	<brief_summary>A phase I study determine maximum tolerable dose ( MTD ) evaluate pharmacokinetic , safety/tolerability efficacy profile antroquinonol ( Hocena® ) non-small cell lung cancer ( NSCLC ) subject refractory conventional treatment modality</brief_summary>
	<brief_title>Determine MTD Evaluate pk , Safety/Tolerability Efficacy Profiles Hocena® NSCLC Subjects</brief_title>
	<detailed_description>1 . Antroquinonol , novel cyclohexenone compound , purify compound extract Antrodia camphorata . 2 . The pharmacological effect antroquinonol postulate exert antitumorigenesis effect interaction primary target epidermal growth factor receptor ( EGFR ) /Akt/mitogen-activated protein kinase ( MAPK ) . 3 . In vivo study NOD/SCID mouse A549 subcutaneous xenograft consistently show tumor growth suppression 2 week oral 30 60 mg/kg antroquinonol treatment .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1 . Age ≥ 20 year . 2 . Diagnosed stage III/IV NSCLC . The grading determine accord TumorNodeMetastasis ( TNM ) stag system lung cancer . 3 . Patients histologically cytologically proven primary NSCLC adenocarcinoma mixed cell type adenocarcinoma , fail standard treatment . 4 . With progressive tumor two line chemotherapy ( include one platinumbased ) 1 EGFRtargeted therapy patient identify EGFR mutation his/her EGFR mutation status unknown OR refuse currently approve treatment modality . 5 . Life expectancy ≥ 3 month . 6 . Within 1 week plan first study treatment day , adequate hematopoietic function present : Total white blood cell ( WBC ) ≥ 3500 cells/mm3 Hemoglobin ( Hb ) ≥ 9.0 g/dL Platelets ≥ 100,000 cells/mm3 Absolute neutrophil count ( ANC ) ≥ 1500 /mm3 7 . Within 1 week plan first study treatment day , adequate hepatic renal function present : Total bilirubin ≤2.0 mg/dLGOLANTA20090911 , Amendment 4/v . 1.0/ 13 October 2010 AST ≤ 3 × upper limit normal ( ULN ) ; patient liver metastasis : AST ≤ 5 × ULN ALT ≤ 3 × ULN ; patient liver metastasis : ALT ≤ 5 × ULN Creatinine ≤ 1.5 mg/dL 8 . Must recover toxicity previous anticancer treatment grade 1 NCICTC good , except alopecia . 9 . Eastern Cooperative Oncology Group ( ECOG ) performance score ≤ 2 . 10 . Female patient childbearing potential confirm pregnant screening ; inform effective contraception must use entire treatment period study 6 month exit study . 11 . Given sign dated write informed consent form . 1 . Primary major surgery &lt; 4 week prior plan first study treatment day . 2 . Lactating , pregnant plan become pregnant . 3 . Except alopecia , recover previous treatment grade 1 less prior plan first study treatment day . 4 . With active systemic infection , active clinically significant cardiac disease , active gastrointestinal ulcer , medical condition may significantly affect adequate absorption investigational product . 5 . Within 5 year , prior history malignancy NSCLC , except cervical carcinoma situ basal squamous cell skin carcinoma . 6 . Known allergic antroquinonol formulation excipients . 7 . Within 14 day plan first study treatment day , expose drug ( ) know significant CYP2C19 , 3A4 , 2C8 , 2E1 , inhibitor activator . 8 . With condition judge investigator unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>